Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
New England Journal of Medicine · 19.06.2025 · 392 (23) · 2321-2333
DOI: 10.1056/nejmoa2503704 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 19.06.2025. Verfasst von John V Heymach und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 135-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
- Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam.
- Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam.
- Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Institut Curie, Institut du Thorax Curie-Montsouris, Paris.
- Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles, France.
ORCID-Profile: Byoung Chul Cho
Förderung
- Boehringer Ingelheim
Zitieren
APA
Heymach, J. V., Ruiter, G., Ahn, M. J., Girard, N., Smit, E. F., Planchard, D., Wu, Y. L., Cho, B. C., Yamamoto, N., Sabari, J. K., Zhao, Y., Tu, H. Y., Yoh, K., Nadal, E., Sadrolhefazi, B., Rohrbacher, M., von Wangenheim, U., Eigenbrod-Giese, S., Zugazagoitia, J., & Beamion LUNG-1 Investigators (2025). Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 392(23), 2321-2333. https://doi.org/10.1056/nejmoa2503704
Vancouver
Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, et al. Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2025;392(23):2321-2333. doi:10.1056/nejmoa2503704
BibTeX
@article{Heymach2025,
author = {Heymach, John V and Ruiter, Gerrina and Ahn, Myung-Ju and Girard, Nicolas and Smit, Egbert F and Planchard, David and Wu, Yi-Long and Cho, Byoung Chul and Yamamoto, Noboru and Sabari, Joshua K and Zhao, Yanqiu and Tu, Hai-Yan and Yoh, Kiyotaka and Nadal, Ernest and Sadrolhefazi, Behbood and Rohrbacher, Maren and von Wangenheim, Ute and Eigenbrod-Giese, Sabina and Zugazagoitia, Jon and Beamion LUNG-1 Investigators, Beamion LUNG-1 Investigators},
title = {Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {23},
pages = {2321--2333},
doi = {10.1056/nejmoa2503704}
}
EUVIMED